CTOs on the Move

Immuno Laboratories

www.immunolabs.com

 
Immuno Laboratories is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

OurLab - Oppenheimer Urologic Reference Laboratory

OurLab - Oppenheimer Urologic Reference Laboratory is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Peoria Tazewell Pathology Group

Peoria Tazewell Pathology Group is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GAMMEX rmi

For nearly 40 years, Gammex has been a leader in the manufacture and distribution of Gammex Lasers patient alignment systems and RMI Quality Control devices for diagnostic imaging and radiation oncology. Founded in 1969 by Dr. Charles Lescrenier,

Alliance HealthCare Services

Alliance HealthCare Services is a leading national provider of outsourced healthcare services providing diagnostic radiology services through its Radiology Division (Alliance HealthCare Radiology), interventional and pain management services through its Interventional Services Division (Alliance Interventional) and radiation oncology services through its Oncology Division (Alliance Oncology). We are the nation`s largest provider of advanced diagnostic mobile imaging services, an industry-leading operator of fixed-site imaging centers, and a leading provider of stereotactic radiosurgery nationwide.

Gritstone Oncology

Gritstone Oncology is a privately-held company headquartered in the San Francisco Bay Area with key functions located in Cambridge, Massachusetts and Pleasanton, California. We launched in October 2015, and since inception, have successfully raised two large, private financing rounds. We currently employ more than 60 professionals. We have brought together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy. With our unique approach to immuno-oncology, we are developing next-generation personalized immunotherapies to fight cancer in patients with the most difficult-to-treat tumors. We plan to combine these personalized neoantigen-targeted therapies with current immune checkpoint modulatory approaches to improve response rates and survival in patients with solid tumors.